title: [Phosphodiesterase type 5 inhibitors for premature ejaculation: advances in studies].
abstract: Premature ejaculation (PE) is a common male sexual disorder with an incidence rate of 20-30%. Recent clinical trials have demonstrated that phosphodiesterase type 5 inhibitors (PDE5i), as the first-line drug for erectile dysfunction (ED), can improve ejaculatory function probably by acting on the peripheral and central adrenergic nerves. The possible action mechanisms of PDE5i may involve lessening of the central sympathetic output, modulation of the contractile responses from the vas deferens, seminal vesicles, prostate and urethra, induction of peripheral analgesia, and prolonging of the total erectile duration, increasing the confidence of ejaculation control, and reducing the post-ejaculation refractory time. This review discusses the possible mechanisms and clinical application of PDE5i in the treatment of PE.
authors.forename: Dun-sheng
authors.initials: DS
authors.lastname: Mo
authors.forename: Xue-jun
authors.initials: XJ
authors.lastname: Shang
authors.forename: Yu-feng
authors.initials: YF
authors.lastname: Huang
mesh_terms: D004542:Ejaculation / Q000187:drug effects; D007172:Erectile Dysfunction / Q000188:drug therapy; D006801:Humans; D008297:Male; D009119:Muscle Contraction; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use*; D061686:Premature Ejaculation / Q000188:drug therapy*; D012669:Seminal Vesicles / Q000502:physiology; D014649:Vas Deferens / Q000502:physiology
chemical_list: D058986:Phosphodiesterase 5 Inhibitors